Volume alert: 210,000 shares traded. Hit a high of .48 before falling back to close at .40. This was an .80 stock a year ago.
Company is consistently quiet, but this line from last week's paid promotion piece at least reiterates that we can expect data soon:
As data from CardioPET’s Phase IIa clinical study is expected to readout this quarter, we expect results in line with the findings of Phase I will be a major catalyst for FPMI shares.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.